This guidance note explores the mechanisms that are available in Europe for extending patent term for regulated pharmaceutical
and plant products to compensate for delays in getting products to market as a result of the long marketing approval process.

This content is restricted to members. To view this content please register or login below to view this content.

Register to receive up-to-date information and advice on tax developments within your industry.